MediciNova receives Notice of Allowance for new patent covering MN-166

MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer. Once issued, this patent is expected to expire no earlier than July 2042. The allowed claims cover the use of MN-166 for preventing, ameliorating, or minimizing metastasis of eye cancer. The allowed claims specifically cover the use of MN-166 for preventing, ameliorating, or minimizing metastasis of uveal melanoma. The allowed claims cover oral administration, a wide range of doses, a range of different dosing frequencies, and a range of different treatment periods.